Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5190MR)

This product GTTS-WQ5190MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5190MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12987MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ2545MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ1760MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ9349MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ11182MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ5442MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ15947MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ1456MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW